Danaher Corporation

Danaher Corporation is an American global science and technology conglomerate that designs, manufactures, and services instruments, consumables, software, and services for the biotechnology, life sciences, and diagnostics industries, generating $24.57 billion in revenue in fiscal 2025. The company traces its roots to a small real estate investment trust taken over by the Rales brothers in 1984 and has since grown — through the systematic application of the Danaher Business System across more than 400 acquisitions — to its current form as a three-segment life sciences and diagnostics platform. Operating through more than fifteen operating companies across approximately fifty countries, Danaher occupies a position at the intersection of drug development, biologics manufacturing, and clinical diagnostics — three markets whose secular growth has been among the most reliable in all of healthcare.

This is, at its core, a story about the Danaher Business System — a management philosophy that has compounded capital at extraordinary rates for four decades by acquiring good industrial assets and making them better. The question today is whether DBS can deliver the same compounding through a portfolio that has tilted decisively toward life sciences and diagnostics, where the moats are deeper but the multiples are higher and the exit valve of a spin-off gets harder to pull. The file turns on whether the bioprocessing recovery has staying power, whether Life Sciences margins can normalize, and whether the Masimo acquisition represents the disciplined capital allocation Danaher is known for or a sign that the pipeline of classic DBS targets is thinning.

The stock closed at $179.14 on July 21, 2026, near the middle of a 52-week range that spans $160.93 to $242.80. At roughly 32 times trailing earnings from continuing operations and 19.5 times trailing EBITDA, the market is pricing in a recovery that has begun to show itself in orders but remains incomplete in reported results. The debate is whether the embedded expectations are reasonable or whether they underestimate both the cyclical tailwinds gathering in bioprocessing and the structural margin headwinds that a goodwill-heavy balance sheet implies.